Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 7/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13735260 | 0.81 | NOTUM (0.49) | NOTUMF2MAPTKCNJ1LMNA | |
| SCHEMBL1460681 | 0.81 | NOTUM (0.53) | NOTUMF2MAPTKCNJ1LMNA | |
| SCHEMBL28360315 | 0.75 | NOTUM (0.59) | NOTUMF2MAPTKCNJ1LMNA | |
| SCHEMBL3819681 | 0.73 | NOTUM (0.61) | NOTUMF2LMNAMEN1KMT2A | |
| SCHEMBL23655426 | 0.71 | NOTUM (0.71) | NOTUMF2MAPTKCNJ1LMNA | |
| SCHEMBL12615985 | 0.71 | NOTUM (0.78) | NOTUMF2MAPTKCNJ1LMNA | |
| SCHEMBL15872005 | 0.70 | NOTUM (0.72) | NOTUMF2MAPTKCNJ1LMNA | |
| SCHEMBL1404600 | 0.68 | NOTUM (0.55) | NOTUMMAPTLMNAALDH1A1MEN1 | |
| SCHEMBL8702581 | 0.67 | NOTUM (0.66) | NOTUMF2MAPTKCNJ1LMNA | |
| SCHEMBL14228219 | 0.67 | NOTUM (0.66) | NOTUMF2MAPTKCNJ1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687492-B2 | 1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-03-30 | — | — | US | claimed |
| US-20080021009-A1 | 1,2,4-Oxadiazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-01-24 | — | — | US | claimed |
| CN-1950349-A | 1,2, 4-oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK & CO INC (US) | 2007-04-18 | — | — | CN | claimed |
| US-7687492-B2 | 1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080021009-A1 | 1,2,4-Oxadiazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-01-24 | — | — | US | disclosed |
| CN-1950349-A | 1,2, 4-oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK & CO INC (US) | 2007-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021009-A1 | 1,2,4-Oxadiazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | NOTUM 1068/4885F2 2350/4885MAPT 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.